Elaine V Jones - 17 Jun 2026 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Reporting relationship: Director
Issuer ticker: CTMX
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2026, 16:45:37 UTC
Prior SEC filing: 24 Jun 2025
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Ogden, as Attorney-in-Fact for Elaine V. Jones

Key filing fact

Elaine V Jones filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 22 Jun 2026.

Key facts

This page summarizes Elaine V Jones's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jun 2026, 16:45.

Change

Previous filing in this sequence was filed on 24 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001296907 Primary reporting owner

Jones Elaine V

Relationship: Director
Address: C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO
Signature: /s/ Christopher Ogden, as Attorney-in-Fact for Elaine V. Jones
Signature date: 22 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTMX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +59,000
Change %
Price: $0.000000^*
Shares after: 59,000
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 59,000
Exercise price: $2.96
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.